114 related articles for article (PubMed ID: 21595304)
21. Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling.
Curtin V; Amharar Y; Hu Y; Erxleben A; McArdle P; Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2013 Jan; 10(1):386-96. PubMed ID: 23186332
[TBL] [Abstract][Full Text] [Related]
22. Vitrification of two active pharmaceutical ingredients by fast scanning calorimetry: From structural relaxation to nucleation phenomena.
Monnier X; Viel Q; Schammé B; Petit S; Delbreilh L; Dupray V; Coquerel G; Dargent E
Int J Pharm; 2018 Jan; 536(1):426-433. PubMed ID: 29225097
[TBL] [Abstract][Full Text] [Related]
23. The Slow Molecular Mobility in Amorphous Ketoprofen and Ibuprofen.
Mora E; Diogo HP; Moura Ramos JJ
J Pharm Sci; 2015 Nov; 104(11):3833-3841. PubMed ID: 26227966
[TBL] [Abstract][Full Text] [Related]
24. Influence of copolymer composition on the phase behavior of solid dispersions.
Prudic A; Kleetz T; Korf M; Ji Y; Sadowski G
Mol Pharm; 2014 Nov; 11(11):4189-98. PubMed ID: 25295846
[TBL] [Abstract][Full Text] [Related]
25. Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites.
Pomázi A; Ambrus R; Sipos P; Szabó-Révész P
J Pharm Biomed Anal; 2011 Sep; 56(2):183-90. PubMed ID: 21652159
[TBL] [Abstract][Full Text] [Related]
26. Impact of chirality on the Glass Forming Ability and the crystallization from the amorphous state of 5-ethyl-5-methylhydantoin, a chiral poor glass former.
Atawa B; Couvrat N; Coquerel G; Dargent E; Saiter A
Int J Pharm; 2018 Apr; 540(1-2):11-21. PubMed ID: 29407191
[TBL] [Abstract][Full Text] [Related]
27. Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation.
Blaabjerg LI; Lindenberg E; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2016 Sep; 13(9):3318-25. PubMed ID: 27529364
[TBL] [Abstract][Full Text] [Related]
28. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of NIR-chemometric methods for chemical and pharmaceutical characterization of meloxicam tablets.
Tomuta I; Iovanov R; Bodoki E; Vonica L
Drug Dev Ind Pharm; 2014 Apr; 40(4):549-59. PubMed ID: 23594301
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical characterization of meloxicam-mannitol binary systems.
Nassab PR; Rajkó R; Szabó-Révész P
J Pharm Biomed Anal; 2006 Jun; 41(4):1191-7. PubMed ID: 16621418
[TBL] [Abstract][Full Text] [Related]
31. Molecular dynamics of the cryomilled base and hydrochloride ziprasidones by means of dielectric spectroscopy.
Kaminski K; Adrjanowicz K; Wojnarowska Z; Grzybowska K; Hawelek L; Paluch M; Zakowiecki D; Mazgalski J
J Pharm Sci; 2011 Jul; 100(7):2642-57. PubMed ID: 21271564
[TBL] [Abstract][Full Text] [Related]
32. Recent advances and potential applications of modulated differential scanning calorimetry (mDSC) in drug development.
Knopp MM; Löbmann K; Elder DP; Rades T; Holm R
Eur J Pharm Sci; 2016 May; 87():164-73. PubMed ID: 26721421
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the crystalline and amorphous states of drug products by nanothermal analysis and Raman imaging.
Nakamoto K; Urasaki T; Hondo S; Murahashi N; Yonemochi E; Terada K
J Pharm Biomed Anal; 2013 Mar; 75():105-11. PubMed ID: 23246930
[TBL] [Abstract][Full Text] [Related]
34. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
35. Impact of in situ granulation and temperature quenching on crystal habit and micromeritic properties of ibuprofen-cationic dextran conjugate crystanules.
Abioye AO; Kola-Mustapha A; Ruparelia K
Int J Pharm; 2014 Feb; 462(1-2):83-102. PubMed ID: 24378327
[TBL] [Abstract][Full Text] [Related]
36. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics.
Cheney ML; Weyna DR; Shan N; Hanna M; Wojtas L; Zaworotko MJ
J Pharm Sci; 2011 Jun; 100(6):2172-81. PubMed ID: 21491441
[TBL] [Abstract][Full Text] [Related]
37. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
Alladi S; Shastri NR
Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of pharmaceutical amorphous solids: the study of enthalpy relaxation by isothermal microcalorimetry.
Liu J; Rigsbee DR; Stotz C; Pikal MJ
J Pharm Sci; 2002 Aug; 91(8):1853-62. PubMed ID: 12115812
[TBL] [Abstract][Full Text] [Related]
39. An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature.
Qi S; Weuts I; De Cort S; Stokbroekx S; Leemans R; Reading M; Belton P; Craig DQ
J Pharm Sci; 2010 Jan; 99(1):196-208. PubMed ID: 19492312
[TBL] [Abstract][Full Text] [Related]
40. Trehalose amorphization and recrystallization.
Sussich F; Cesàro A
Carbohydr Res; 2008 Oct; 343(15):2667-74. PubMed ID: 18768170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
